+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Hemophilia Treatment Market Research Report by Product Type, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4829909
  • Report
  • June 2020
  • Region: Global
  • 221 pages
  • 360iResearch™
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Hemophilia Treatment Market to Grow USD 15,600.22 Million by 2025, at a CAGR of 5.41%


  • Bayer AG
  • Biotest AG
  • Genentech, Inc.
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Shire Plc
  • MORE
The Global Hemophilia Treatment Market is expected to grow from USD 11,370.55 Million in 2019 to USD 15,600.22 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.41%.

Market Segmentation & Coverage:

This research report categorizes the Hemophilia Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Product Type, the Hemophilia Treatment Market is examined across Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.

On the basis of Disease Indication, the Hemophilia Treatment Market is examined across Hemophilia A, Hemophilia B, and Polyethylene.

On the basis of Distribution, the Hemophilia Treatment Market is examined across E-commerce, Hospital Pharmacies, and Retail Pharmacies.

On the basis of Geography, the Hemophilia Treatment Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Hemophilia Treatment Market including Baxter International, Inc., Bayer AG, Biogen Inc., Biotest AG, Chugai Pharmaceutical Co., Ltd., CSL Ltd., Genentech, Inc., Grifols S.A., Kedrion Biopharma Inc., Novo Nordisk A/S, Octapharma AG, Pfizer, Inc., Shire Plc, Spark Therapeutics, Inc., and Swedish Orphan Biovitrum AB.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hemophilia Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Hemophilia Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hemophilia Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hemophilia Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Hemophilia Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Hemophilia Treatment Market?
6. What are the modes and strategic moves considered suitable for entering the Global Hemophilia Treatment Market?
Note: Product cover images may vary from those shown
2 of 3


  • Bayer AG
  • Biotest AG
  • Genentech, Inc.
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Shire Plc
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Product Type Outlook
3.3. Disease Indication Outlook
3.4. Distribution Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Hemophilia Treatment Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers Rising diagnostic and awareness related to Hemophilia Increasing demand for recombinant and plasma-derived factor VIII and factor IX
5.1.2. Restraints Serious adverse effects associated with plasma-derived products Stringent government regulations
5.1.3. Opportunities Increased diagnosis rate and rise in the use of prophylactic treatment
5.1.4. Challenges High cost of recombinant products

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations

7. Global Hemophilia Treatment Market, By Product Type
7.1. Introduction
7.2. Antifibrinolytic Agents
7.3. Desmopressin
7.4. Plasma Derived Coagulation Factor Concentrates
7.5. Recombinant Coagulation Factor Concentrates

8. Global Hemophilia Treatment Market, By Disease Indication
8.1. Introduction
8.2. Hemophilia A
8.3. Hemophilia B
8.4. Polyethylene

9. Global Hemophilia Treatment Market, By Distribution
9.1. Introduction
9.2. E-commerce
9.3. Hospital Pharmacies
9.4. Retail Pharmacies

10. Americas Hemophilia Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Hemophilia Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. South Korea
11.10. Thailand

12. Europe, Middle East & Africa Hemophilia Treatment Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding

14. Company Usability Profiles
14.1. Baxter International, Inc.
14.2. Bayer AG
14.3. Biogen Inc.
14.4. Biotest AG
14.5. Chugai Pharmaceutical Co., Ltd.
14.6. CSL Ltd.
14.7. Genentech, Inc.
14.8. Grifols S.A.
14.9. Kedrion Biopharma Inc.
14.10. Novo Nordisk A/S
14.11. Octapharma AG
14.12. Pfizer, Inc.
14.13. Shire Plc
14.14. Spark Therapeutics, Inc.
14.15. Swedish Orphan Biovitrum AB

15. Appendix
15.1. Discussion Guide
15.2. Edition Details
15.3. License Details
15.4. Pricing Details
Note: Product cover images may vary from those shown
3 of 3
  • Baxter International, Inc.
  • Bayer AG
  • Biogen Inc.
  • Biotest AG
  • Chugai Pharmaceutical Co., Ltd.
  • CSL Ltd.
  • Genentech, Inc.
  • Grifols S.A.
  • Kedrion Biopharma Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer, Inc.
  • Shire Plc
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
Note: Product cover images may vary from those shown